CARES-310 Study Final Analysis Published in The Lancet
Camrelizumab plus rivoceranib delivered a median overall survival of 23.8 months versus 15.2 months on sorafenib in first-line unresectable...
Inspira’s Lab Breakthrough Accelerates Blood Diagnostics Tech
Inspira Technologies is expanding its core blood laboratory operations, moving into a larger facility with upgraded instrumentation and plans...
First Patient Dosed in Crinetics’ Neuroendocrine Tumor Trial
Crinetics has dosed the first patient in BRAVESST2, a first-in-human Phase 1/2 study of CRN09682 in metastatic or locally...
Relmada Presents NDV-01 Phase 2 Urologic Oncology Data
NDV-01, a sustained-release intravesical gemcitabine/docetaxel formulation, has reported a 92% complete response at any time point at nine months...
Capricor’s Hopeful DMD Drug Sees Phase 3 Pivotal Victory
In the pivotal Phase 3 HOPE-3 trial (n=106), Deramiocel slowed decline on PUL v2.0 by 54% versus placebo (p=0.029)...
Italy Approves Betaglue’s Pancreatic Cancer Clinical Trial
BetaGlue Therapeutics has secured Italian Ministry of Health approval for a clinical investigation of YntraDose in unresectable locally advanced...
Phase 3 STELLAR Study Shows Improvements in Rare Brain Tumor
Median overall survival reached 34.9 months with eflornithine plus lomustine versus 23.5 months with lomustine alone in patients with...
FDA Approves Reduced Enrollment for Quelimmune Pediatric Study
Early real-world use of SeaStar Medical’s QUELIMMUNE in pediatric septic acute kidney injury has shown zero device-related adverse events...
New Nebokitug Phase 2 Results Published for Sclerosing Cholangitis
Nebokitug was safe and well tolerated through 48 weeks in primary sclerosing cholangitis, with a statistically significant reduction in...
BriaCell to Present Phase 2/3 Clinical & Survival Data
Topline: An interim pooled analysis from BriaCell’s ongoing pivotal Phase 3 in metastatic breast cancer reported an “excellent” safety...